Latest News & Features
Europe
A German Federal Court decision has given patent applicants in the life sciences field plenty to think about,
as Wolfgang Bublak and Axel Berger explain. 16 October 2013
Asia
LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world. 16 October 2013
Biotechnology
When the US Supreme Court decided in favour of Monsanto in its case against a soybean farmer, it clarified the patent status of certain self-replicating technologies. In Europe, the result would probably have been the same, say Steven Zeman and Heike Vogelsang-Wenke. 16 October 2013
Americas
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain. 16 October 2013
Asia
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators. 16 October 2013
Americas
Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach. 30 September 2013
Big Pharma
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products. 30 September 2013
Biotechnology
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit. 30 September 2013
Big Pharma
A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR. 31 August 2013
Americas
In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP. 31 August 2013